Overview Dividends

(BCPC) Balchem - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0576652004

Choline, Encapsulated Nutrients, Sterilants, Propylene Oxide, Chelated Minerals

BCPC EPS (Earnings per Share)

EPS Growth (3Y CAGR): 14.07%
EPS Trend (3Y Correlation): 92.5%

BCPC Revenue

Revenue Growth (3Y CAGR): 5.23%
Revenue Trend (3Y Correlation): 85.6%

Description: BCPC Balchem November 05, 2025

Balchem Corporation (NASDAQ: BCPC) manufactures specialty performance ingredients for a broad set of markets-including human nutrition, animal health, and industrial sterilization-organized into three operating segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

In FY 2023 the company generated roughly $2.2 billion in revenue, with an operating margin of about 12 % and a 5 % year-over-year increase driven primarily by higher demand for its vitamin K2 and microencapsulation platforms in functional foods and dietary supplements. A key sector catalyst is the accelerating consumer shift toward fortified, “clean-label” products, which is expanding the addressable market for Balchem’s spray-dried powders and lipid delivery systems. On the animal side, tighter regulations on antibiotic use are boosting adoption of chelated minerals and choline-based feed additives, supporting the segment’s double-digit growth trajectory.

For a deeper, data-rich assessment of Balchem’s valuation dynamics, you may find it worthwhile to explore the company’s profile on ValueRay, where additional quantitative metrics and scenario analyses are available.

BCPC Stock Overview

Market Cap in USD	4,946m
Sub-Industry	Specialty Chemicals
IPO / Inception	1986-06-03

BCPC Stock Ratings

Growth Rating	-6.53%
Fundamental	78.1%
Dividend Rating	48.6%
Return 12m vs S&P 500	-27.3%
Analyst Rating	4.0 of 5

BCPC Dividends

Dividend Yield 12m	0.57%
Yield on Cost 5y	0.88%
Annual Growth 5y	10.67%
Payout Consistency	98.3%
Payout Ratio	17.5%

BCPC Growth Ratios

Growth Correlation 3m	-68.5%
Growth Correlation 12m	-69.4%
Growth Correlation 5y	67.5%
CAGR 5y	3.12%
CAGR/Max DD 3y (Calmar Ratio)	0.14
CAGR/Mean DD 3y (Pain Ratio)	0.38
Sharpe Ratio 12m	-0.96
Alpha	-29.23
Beta	0.994
Volatility	22.87%
Current Volume	123.9k
Average Volume 20d	174k
Stop Loss	147.6 (-3%)
Signal	0.79

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (149.2m TTM) > 0 and > 6% of Revenue (6% = 60.8m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA -0.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 21.44% (prev 22.98%; Δ -1.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 201.6m > Net Income 149.2m (YES >=105%, WARN >=100%)

Net Debt (90.7m) to EBITDA (257.7m) ratio: 0.35 <= 3.0 (WARN <= 3.5)

Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (32.7m) change vs 12m ago -0.25% (target <= -2.0% for YES)

Gross Margin 35.82% (prev 34.47%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 62.22% (prev 59.01%; Δ 3.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 18.60 (EBITDA TTM 257.7m / Interest Expense TTM 10.9m) >= 6 (WARN >= 3)

Altman Z'' 7.22

(A) 0.13 = (Total Current Assets 343.7m - Total Current Liabilities 126.4m) / Total Assets 1.66b

(B) 0.67 = Retained Earnings (Balance) 1.11b / Total Assets 1.66b

(D) 3.19 = Book Value of Equity 1.16b / Total Liabilities 363.2m

Total Rating: 7.22 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 78.06

1. Piotroski 8.0pt = 3.0

2. FCF Yield 3.21% = 1.60

3. FCF Margin 15.94% = 3.99

4. Debt/Equity 0.12 = 2.49

5. Debt/Ebitda 0.35 = 2.41

6. ROIC - WACC (= 2.01)% = 2.51

7. RoE 12.12% = 1.01

8. Rev. Trend 85.64% = 6.42

9. EPS Trend 92.54% = 4.63

What is the price of BCPC shares?

As of November 07, 2025, the stock is trading at USD 152.23 with a total of 123,868 shares traded.
Over the past week, the price has changed by -1.13%, over one month by +6.34%, over three months by -4.86% and over the past year by -16.57%.

Is Balchem a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Balchem (NASDAQ:BCPC) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 78.06 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCPC is around 129.54 USD . This means that BCPC is currently overvalued and has a potential downside of -14.91%.

Is BCPC a buy, sell or hold?

Balchem has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BCPC.

Strong Buy: 0
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BCPC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	200.7	31.8%
Analysts Target Price	200.7	31.8%
ValueRay Target Price	145.3	-4.6%

BCPC Fundamental Data Overview November 07, 2025

Market Cap USD = 4.95b (4.95b USD * 1.0 USD.USD)
P/E Trailing = 33.4158
P/E Forward = 29.2398
P/S = 4.8796
P/B = 3.7439
P/EG = 3.7539
Beta = 0.994
Revenue TTM = 1.01b USD
EBIT TTM = 202.0m USD
EBITDA TTM = 257.7m USD
Long Term Debt = 190.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 202.0k USD (from shortTermDebt, last quarter)
Debt = 155.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 90.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.04b USD (4.95b + Debt 155.8m - CCE 65.1m)
Interest Coverage Ratio = 18.60 (Ebit TTM 202.0m / Interest Expense TTM 10.9m)
FCF Yield = 3.21% (FCF TTM 161.6m / Enterprise Value 5.04b)
FCF Margin = 15.94% (FCF TTM 161.6m / Revenue TTM 1.01b)
Net Margin = 14.72% (Net Income TTM 149.2m / Revenue TTM 1.01b)
Gross Margin = 35.82% ((Revenue TTM 1.01b - Cost of Revenue TTM 650.5m) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 36.45%)
Tobins Q-Ratio = 3.03 (Enterprise Value 5.04b / Total Assets 1.66b)
Interest Expense / Debt = 1.51% (Interest Expense 2.35m / Debt 155.8m)
Taxrate = 22.59% (11.8m / 52.0m)
NOPAT = 156.4m (EBIT 202.0m * (1 - 22.59%))
Current Ratio = 2.72 (Total Current Assets 343.7m / Total Current Liabilities 126.4m)
Debt / Equity = 0.12 (Debt 155.8m / totalStockholderEquity, last quarter 1.30b)
Debt / EBITDA = 0.35 (Net Debt 90.7m / EBITDA 257.7m)
Debt / FCF = 0.56 (Net Debt 90.7m / FCF TTM 161.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 149.2m / Total Assets 1.66b)
RoE = 12.12% (Net Income TTM 149.2m / Total Stockholder Equity 1.23b)
RoCE = 14.21% (EBIT 202.0m / Capital Employed (Equity 1.23b + L.T.Debt 190.0m))
RoIC = 11.18% (NOPAT 156.4m / Invested Capital 1.40b)
WACC = 9.17% (E(4.95b)/V(5.10b) * Re(9.42%) + D(155.8m)/V(5.10b) * Rd(1.51%) * (1-Tc(0.23)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.35%
[DCF Debug] Terminal Value 76.33% ; FCFE base≈162.0m ; Y1≈190.6m ; Y5≈291.5m
Fair Price DCF = 120.6 (DCF Value 3.91b / Shares Outstanding 32.4m; 5y FCF grow 18.81% → 3.0% )
EPS Correlation: 92.54 | EPS CAGR: 14.07% | SUE: 4.0 | # QB: 2
Revenue Correlation: 85.64 | Revenue CAGR: 5.23% | SUE: 1.65 | # QB: 1

Additional Sources for BCPC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle